Effects of sodium-glucose cotransporter 2 inhibitors on pulmonary hemodynamics in chronic heart failure patients and a pulmonary artery pressure sensor: does left ventricular ejection fraction matter?

11 May 2024 (08:00 - 20:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Evelyn Santiago-Vacas

University Hospital Germans Trias and Pujol de Badalona, Badalona (Spain)

4 More presentations in this session

Presentation thumbnail

Impact of beta-blocker therapy in patients with preserved left ventricular ejection fraction after ST-segment elevation myocardial infarction

Doctor C. Carvalho (Viana do Castelo, PT)

Abstract Slides Video

Presentation thumbnail

Impact of the guideline-directed medical therapy on the eligibility of patients for mitral valve transcatheter edge-to-edge repair in HFrEF

Doctor B. Muk (Budapest, HU)

Abstract Slides Video

Presentation thumbnail

Beyond assumptions: NT-proBNP rise and diuretic strategies in HFrEF therapy up-titration

Doctor D. Ferreira (Lisbon, PT)

Abstract Slides Video

Presentation thumbnail

Initial 6-hour injectable diuretic therapy on 24-month outcomes in acute heart failure patients

Doctor A. Singh (Manipal, IN)

Abstract Slides Video

Access the full session

Session thumbnail

Chronic heart failure - treatment 13

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

You may be interested in

Congress Presentation

Effects of sodium-glucose cotransporter 2 inhibitors on pulmonary hemodynamics in chronic heart failure patients with a pulmonary artery pressure sensor.

Congress Presentation

Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

Congress Presentation

Unravel novel therapeutic targets in heart failure and associated pulmonary hypertension

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources